Accuray Incorporated (Nasdaq: ARAY) announced this week that the InCise Multileaf Collimator (MLC) for the CyberKnife M6 System will now be available outside the United States in markets where it is approved for sale, in addition to the U.S. market where the InCise MLC was commercially launched in February 2015. The launch follows the successful completion of the evaluation of the InCise MLC by Erasmus MC Cancer Institute in Rotterdam, the Netherlands, the European evaluation site working in collaboration with Accuray. Two sites in the United States. had previously completed their evaluation of the InCise MLC. The main benefits of the MLC reported by the sites were the ability to treat a broader range of tumors than they could with fixed collimators or the Iris Collimator, and to do so with significantly increased efficiency. The InCise MLC will be featured at the European Society for Therapeutic Radiology and Oncology (ESTRO) meeting in Barcelona, Spain, April 24-27.
"We are continuing to advance our successful CyberKnife M6 System platform, through the introduction of the InCise MLC. The addition of the InCise MLC enhances the M6 system's functionality by significantly reducing treatment times and expands its versatility by broadening the range of patients and tumors that can be treated," said Joshua H. Levine, president and CEO of Accuray in a press release. "We believe the M6, with the MLC, will enable clinicians to treat tumors they may have thought to be untreatable with SBRT, efficiently and with precise dose delivery."
The InCise MLC is the world's first multileaf collimator to be available on a robotic platform, the CyberKnife M6 System. The system's robotic design enables physicians to find the best angles for radiation to enter and exit the body, maximizing dose to the target while minimizing exposure to healthy tissue. The robotic design also enables the system to adjust and automatically stay on target in real-time, accounting for patient and tumor motion. The CyberKnife M6 System can be used to treat tumors anywhere in the body, including the prostate, lung, brain, spine, liver, pancreas and kidney, and may offer hope to patients who have inoperable or surgically complex tumors, or who may prefer a clinically effective, nonsurgical option.Back To Top
April 22 - Accuray Initiates International Launch of the InCise MLC for the CyberKnife M6 . Appl Rad Oncol.